NCT04792190View on ClinicalTrials.gov

Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation

PHASE4CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 27, 2021

Primary Completion Date

March 31, 2023

Study Completion Date

June 30, 2023

Conditions
Atrial Fibrillation
Interventions
DRUG

dapagliflozin

Subjects will take 1 blinded tablet of study drug (dapagliflozin 10 mg) dosed once daily, for 12 months.

DRUG

Placebo

Subjects will take 1 blinded capsule of placebo drug dosed once daily

Trial Locations (3)

14642

University of Rochester Medical Center, Rochester

48202

Henry Ford Hospital, Detroit

04102

Maine Medical Center, Portland

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University of Rochester

OTHER

NCT04792190 - Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation | Biotech Hunter | Biotech Hunter